# Pegylated Liposomal Doxorubicin Versus Daunorubicin to Treat Acute Lymphoblastic Leukemia:

> **NCT02070523** · PHASE3 · UNKNOWN · sponsor: **Changzhou Jinyuan Pharmaceutical Manufacturing Co., Ltd.** · enrollment: 200 (estimated)

## Conditions studied

- Acute Lymphoblastic Leukemia

## Interventions

- **DRUG:** VDCLD regimen

## Key facts

- **NCT ID:** NCT02070523
- **Lead sponsor:** Changzhou Jinyuan Pharmaceutical Manufacturing Co., Ltd.
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2013-12
- **Primary completion:** 2015-11
- **Final completion:** 2015-12
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2014-07-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02070523

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02070523, "Pegylated Liposomal Doxorubicin Versus Daunorubicin to Treat Acute Lymphoblastic Leukemia:". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02070523. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*